Combined therapy of Chinese medicine with in vitro fertilization and embryo transplantation for treatment of polycystic ovarian syndrome

Fang Lian et al, Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Nov ;28 (11):977-80
Chinese Journal of Integrated Traditional and Western medicine

IVF patients in this country are generally advised not to take Chinese herbs during their IVF cycle, to avoid drug interactions, however in China they often combine therapies if they feel it will benefit the patient.

In this small RCT, IVF patients with PCOS were given a herbal formula during the IVF cycle. The group in this study who received the herbs had significantly better uterine linings, used lower doses of FSH and had a higher pregnancy rate. Additionally the incidence of hyperstimulation was reduced in the herb group. Trials with larger numbers will be needed to support these findings before conclusions can be made. 


OBJECTIVE: To evaluate the validity of Chinese drugs for reinforcing Shen and regulating Chong channel (RSRCC) on patients with polycystic ovarian syndrome (PCOS) undergoing in vitro fertilization and embryo transplantation (IVF-ET).
METHODS: Sixty-four patients with PCOS undergoing IVF-ET were randomly assigned to two groups, the treated group (36 cases) and the control group (28 cases), to the former, Chinese recipe for RSRCC was given additionally.
RESULTS: On the human chorionic gonadotrophin (HCG) injecting day, the percentage of three-line sign of endometrium (type A) in the treated group was 75.0%(27/36), which was higher than that in the control group (42.9%, 12/28), showing significant difference between the two groups (P < 0.01). The rates of mature oocytes, fertilization, high-qualified embryo rate, clinical pregnancy rate and incidence rate of ovary hyper-stimulating syndrome (OHSS) in the treated group were (76.8 +/- 8.2)%,(73.5 +/- 8.9)%,(89.4 +/- 14.4)%, 36.11%(13/36) and 5.56%(2/36), respectively; whereas those in the control group (64.4 +/- 8.7)%,(68.2 +/- 10.0)%,(79.5 +/- 15.2)%, 21.43%(6/28) and 10.71%(3/28); the dosage of gonadotrophin administered in the treated group was 33.8 +/- 12.5 ampoules, and in the control group 47.6 +/- 18.2 amp oules, statistical significance was shown between groups in comparing all the above-mentioned parameters (P <0.05, P <0.01). However, the number of oocytes obtained in the two groups was insignificantly different (P > 0.05).

CONCLUSION: Combined use of Chinese drugs for RSRCC in IVF-ET can reduce the dosage of gonadotrophin administered and raise the clinical pregnant rate.